-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Upgrades enGene Therapeutics to Overweight, Raises Price Target to $6

Benzinga·11/12/2026 12:28:02
Wells Fargo analyst Yanan Zhu upgrades enGene Therapeutics (NASDAQ:ENGN) from Equal-Weight to Overweight and raises the price target from $2 to $6.